Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
Head-to-head evidence comparison — which supplement is right for you?
Bimatoprost (lashes) vs Tazarotene: Bimatoprost (lashes) has the stronger overall evidence (8 vs 7.5/10); the best pick depends on your goals. Take the 2-minute quiz for a pick tailored to your goals.
Bimatoprost (lashes) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
1 of 1 studies with measurable effects showed benefit.
Top outcomes
Verdict
Too few graded studies
Top outcomes
Prescription topical. Bimatoprost 0.03% is applied once daily as a thin line to the skin of the UPPER eyelid margin at the lash base (not to the lower lid, and avoid getting it in the eye), using a fresh applicator per eye. Continuous use is needed to maintain results. Use under a clinician, especially if you have glaucoma or take prostaglandin eye drops. There is no oral or systemic use. This library does not provide an ingestion protocol.
Evening
Bimatoprost 0.03% solution (Latisse) with single-use applicators, under a clinician
A source-matched dose range is not available for this product and use.
If this treatment was prescribed for you, follow your prescriber’s directions. Do not change prescribed treatment because this page has no matched dose range.
Evening
Tazarotene 0.045% lotion
Throughout
8-16 weeks
2-6 months after stopping
Weeks to months
immediate
12 weeks
24 weeks
1-4 weeks
Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial.
Br J Dermatol (2015) · RCT
1-year double-masked RCT: composite primary endpoint (Global Eyelash Assessment + satisfaction) met for bimatoprost vs vehicle in idiopathic (40.2% vs 6.8%) and post-chemotherapy (37.5% vs 18.2%) hypotrichosis
Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies.
Aesthetic Plast Surg (2014) · RCT · n=209
Two double-masked vehicle-controlled RCTs (n=209: 173 idiopathic, 36 chemotherapy-induced) in Japanese subjects
The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis.
Front Med (Lausanne) (2023) · Meta-Analysis
Meta-analysis of six placebo-controlled RCTs of topical prostaglandin analogs (incl. bimatoprost) for hair growth (lashes, brows, scalp)
Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials
J Drugs Dermatol (2020) · RCT · n=1614
The two identical phase 3 registration trials for the 0.045% lotion — 1614 subjects aged 9 and older.
New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis
J Drugs Dermatol (2020) · RCT · n=684
A pooled paediatric SUBGROUP analysis of the two phase 3 trials, not a separate trial: 136 patients aged 10-13 and 548 aged 14-17.
Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial
Arch Dermatol (2002) · RCT · n=563
The long photodamage trial: 24 weeks double-blind, then a 28-week open-label extension — 12 months in total, 563 patients.
Bimatoprost (lashes) has a higher evidence score (8/10 vs 7.5/10) and wins in 2 of 3 categories.
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.